1/ I wanted to include this as its science needs to be understood, even though, they are technically a company with indications or even public to value. I really love the application of the science.
2/ The Prime Editing comes with 3 parts and its more of a gene writer than a base editor. It has the CAS enzyme that cuts the DNA using a single strand nickase. The guide RNA is much larger, but plays 2 roles. The first half guides the CAS enzyme to the site of the edit.
3/ The second half of the RNA is used as the template for the Reverse Transcriptase (RT). The Reverse transcriptase is the part that copies the RNA into the DNA.
4/ A reverse transcriptase is from a Retrovirus like HIV. There are many, many of them. That is how Lentivirus does its insertion. It takes an RNA template and copies it into the DNA.
5/ The big difference is the Lentivirus is not guided while the CAS system guides the RT in the Prime Editing.
6/ This system is brilliant as it take the best part of CRISPR with guided editing and pairs it with the best part of the RT to copy a template into the DNA.
7/ I can see a few issues that might happen with this system. The first is the guide RNA might still go off target. The other is around how the insertion of the RT created DNA is inserted and ligated.
8/ I wonder if there is any room for off target insertion of the created DNA that is synthesized. I know I asked about how they limit the RT to using the template strand and got a great answer.
9/ They have a load sequence that prevents the RT from using some random RNA already in the cell.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/ This company uses CRISPR CAS9 in a whole new approach. They use a CAS9 enzyme along with the guide RNA to find the right place in the Genome and do a Double Stranded Break (DSB).
2/ Then they use a second AAV6 vector to deliver a template strand of DNA that the cell can use for Homology Directed Repair (HDR). I looked at this approach, and I see so many things that could go wrong.
1/ This is probably my least favorite of the CRISPR companies. They just licensed all the base editing tech for use in liver diseases around cholesterol from $BEAM. They even licensed their use of the LNP vectors from another company.
2/ Other than their biology understanding of these diseases, I don't know what they actually bring to the table. They are focused on PCSK9 for their lead asset. The preclinical data looks good. This technology still has all the same concerns in humans a the $BEAM base editors.
1/ This is the first company to take CRISPR and modify it for base editing. It uses the CAS9 enzyme that is modified for cutting only 1 strand of the DNA. It is called a nickase. The guide is the same. They add an additional enzyme called deaminase.
2/ The guide works the same to find the right place in the DNA. It can still have off target effects like any guide RNA. That part has not been eliminated. What has been changed is only 1 strand of the DNA gets cut.
1/ This might be the most recent of CRISPR IPO's, but its one of the oldest companies with this technology. Rachel was part of the Jennifer Doudna team, and they worked together to form $CRBU.
2/ I followed this company for a long time as a private company when I got interested in CRISPR a few years ago. They are the holder of all the Doudna patents for CAS9 and CAS12. They license completely the CAS9 to $NTLA which they did for a share stake in the company.
1/ This is the first CRISPR company to start using the CAS12 enzyme. It was formerly known as cpf1 if you ever see that term. It is a smaller structure than CAS9 with CAS9 being about 4.1kb big and CAS12 3.8kb big.
2/ That makes it fit into an AAV vector for delivery and leaves room for other necessary components. The CAS12 enzyme also makes a staggered cut in the DNA which is far more favorable with the repair machinery of the cell to fix the breaks without indels.
1/ They are the other CRISPR company using the original CAS9 enzyme for editing. This enzyme has all the same risks as for $NTLA with potential off target edits and mutations. It still has all the versatility too. That is one of its great benefits. It can insert and delete.
2/ One of the nice things about $CRSP is they have been focused on all indications outside of the body. Their lead programs are in stem cells, T cells and regenerative medicines.